Christopher Sjwall

List of Publications by Citations

Source: https://exaly.com/author-pdf/7612358/christopher-sjowall-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141
papers2,691
citations31
h-index44
g-index179
ext. papers3,574
ext. citations4.7
avg, IF5.22
L-index

#	Paper	IF	Citations
141	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017 , 8, 16021	17.4	171
140	Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjgren@ syndrome. <i>Genes and Immunity</i> , 2011 , 12, 100-9	4.4	97
139	DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 736-743	2.4	76
138	Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. <i>Arthritis Research</i> , 2004 , 6, R87-94		71
137	Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register. <i>Arthritis Research and Therapy</i> , 2015 , 17, 3	5.7	67
136	A single nucleotide polymorphism in the gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1607-1613	2.4	65
135	Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3755-60		63
134	Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. <i>European Journal of Human Genetics</i> , 2013 , 21, 994-9	5.3	62
133	Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. <i>PLoS ONE</i> , 2013 , 8, e84450	3.7	62
132	Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1544-1549	2.4	61
131	Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017 , 16, 343-351	13.6	52
130	Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sj\(\)gren\(\)gr	·66 ^{5.5}	50
129	Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus. <i>Lupus</i> , 2015 , 24, 569-81	2.6	48
128	What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLE. <i>Arthritis Care and Research</i> , 2016 , 68, 988-94	4.7	42
127	Association between genetic variants in the tumour necrosis factor/lymphotoxin ¶lymphotoxin □ locus and primary Sjogren@ syndrome in Scandinavian samples. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 981-8	2.4	41
126	Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity. <i>Journal of Rheumatology</i> , 2015 , 42, 817-25	4.1	40
125	The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. <i>Journal of Immunological Methods</i> , 2018 , 459, 11-19	2.5	40

124	Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. <i>Translational Research</i> , 2013 , 162, 287-96	11	39
123	High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 363-369	2.4	39
122	Association of genes in the NF- B pathway with antibody-positive primary Sjgren@syndrome. <i>Scandinavian Journal of Immunology</i> , 2013 , 78, 447-54	3.4	37
121	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	37
120	Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. <i>Clinica Chimica Acta</i> , 2007 , 378, 13-23	6.2	36
119	Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2008 , 35, 1994-2000	4.1	35
118	The diagnostic accuracies of the 2012 SLICC criteria and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification are comparable. <i>Lupus</i> , 2019 , 28, 778-782	2.6	33
117	Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. <i>BMJ Open</i> , 2013 , 3, e003608	3	33
116	Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis. <i>PLoS ONE</i> , 2016 , 11, e0165373	3.7	33
115	Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. <i>Human Genetics</i> , 2019 , 138, 141-150	6.3	32
114	Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1363-13	3 70	32
113	Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus. Journal of Autoimmunity, 2004 , 22, 315-23	15.5	32
112	Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. <i>Arthritis Research and Therapy</i> , 2016 , 18, 289	5.7	32
111	Novel risk genes for systemic lupus erythematosus predicted by random forest classification. <i>Scientific Reports</i> , 2017 , 7, 6236	4.9	31
110	Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. <i>Arthritis Research and Therapy</i> , 2009 , 11, R188	5.7	31
109	Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 320-327	2.4	31
108	Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. <i>BMC Musculoskeletal Disorders</i> , 2015 , 16, 188	2.8	30
107	Complement opsonization of HIV-1 results in decreased antiviral and inflammatory responses in immature dendritic cells via CR3. <i>Journal of Immunology</i> , 2014 , 193, 4590-601	5.3	30

106	Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sj\(\)gren\(6.2	30
105	Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 352, 251-8	3.4	30
104	Common genetic variations in the NALP3 inflammasome are associated with delayed apoptosis of human neutrophils. <i>PLoS ONE</i> , 2012 , 7, e31326	3.7	29
103	Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). <i>Rheumatology</i> , 2018 , 57, 1400-1407	3.9	28
102	Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis. <i>Cell Reports</i> , 2016 , 16, 2928-2939	10.6	28
101	Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015 , 17, 338	5.7	26
100	No evidence of pathogenic involvement of cathelicidins in patient cohorts and mouse models of lupus and arthritis. <i>PLoS ONE</i> , 2014 , 9, e115474	3.7	26
99	C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. <i>Autoimmunity</i> , 2013 , 46, 205-14	3	26
98	Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus. <i>Frontiers in Pharmacology</i> , 2019 , 10, 82	5.6	24
97	Systemic lupus erythematosus prevalence in Sweden in 2010: what do national registers say?. <i>Arthritis Care and Research</i> , 2014 , 66, 1710-7	4.7	24
96	Case definitions in Swedish register data to identify systemic lupus erythematosus. <i>BMJ Open</i> , 2016 , 6, e007769	3	24
95	Association of serum C-reactive protein levels with lupus disease activity in the absence of measurable interferon-land a C-reactive protein gene variant. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1568-73	9.5	23
94	Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. <i>Translational Research</i> , 2015 , 165, 658-66	11	22
93	Contribution of IKBKE and IFIH1 gene variants to SLE susceptibility. <i>Genes and Immunity</i> , 2013 , 14, 217-	2 4 .4	22
92	B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. <i>Frontiers in Medicine</i> , 2020 , 7, 316	4.9	21
91	Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1063-1069	2.4	21
90	Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. <i>Scandinavian Journal of Rheumatology</i> , 2014 , 43, 428-30	1.9	21
89	International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies. <i>Lupus</i> , 2016 , 25, 864-72	2.6	20

88	Shared and Unique Patterns of DNA Methylation in Systemic Lupus Erythematosus and Primary Sjgren@Syndrome. <i>Frontiers in Immunology</i> , 2019 , 10, 1686	8.4	20
87	Soluble urokinase plasminogen activator receptora valuable biomarker in systemic lupus erythematosus?. <i>Clinica Chimica Acta</i> , 2015 , 444, 234-41	6.2	19
86	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. <i>Journal of Hepatology</i> , 2014 , 60, 1259-67	13.4	18
85	High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. <i>Human Immunology</i> , 2012 , 73, 382-8	2.3	18
84	NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 254-261	2.4	18
83	Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy. <i>Clinical and Experimental Immunology</i> , 2017 , 189, 372-382	6.2	17
82	Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. <i>Clinica Chimica Acta</i> , 2009 , 400, 128-31	6.2	16
81	Beware of antibodies to dietary proteins in "antigen-specific" immunoassays! falsely positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project). <i>Journal of Rheumatology</i> , 2011 , 38, 215-20	4.1	15
80	C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin. <i>Immunology and Cell Biology</i> , 2008 , 86, 466-74	5	15
79	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 106, 102340	15.5	15
78	Sex differences in clinical presentation of systemic lupus erythematosus. <i>Biology of Sex Differences</i> , 2019 , 10, 60	9.3	15
77	Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. <i>Lupus</i> , 2017 , 26, 1333-1338	2.6	14
76	Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE. <i>Lupus Science and Medicine</i> , 2017 , 4, e000225	4.6	14
75	Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. <i>Clinical and Experimental Immunology</i> , 2020 , 199, 245-254	6.2	14
74	Cervical neoplasia in systemic lupus erythematosus: a nationwide study. <i>Rheumatology</i> , 2017 , 56, 613-6	19 .9	14
73	Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 684-90	5.3	12
7 ²	Low Production of Reactive Oxygen Species Drives Systemic Lupus Erythematosus. <i>Trends in Molecular Medicine</i> , 2019 , 25, 826-835	11.5	12
71	Neutrophil Extracellular Traps (NETs) in the Cerebrospinal Fluid Samples from Children and Adults with Central Nervous System Infections. <i>Cells</i> , 2019 , 9,	7.9	12

70	Interferon-Itoincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro. <i>Clinical and Experimental Immunology</i> , 2017 , 189, 83-91	6.2	11	
69	Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11	
68	Complement Opsonization Promotes Herpes Simplex Virus 2 Infection of Human Dendritic Cells. Journal of Virology, 2016 , 90, 4939-4950	6.6	11	
67	The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts. <i>Lupus</i> , 2019 , 28, 1261-12	7 2 .6	11	
66	Smoking reduces the efficacy of belimumab in mucocutaneous lupus. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 911-920	5.4	11	
65	A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. <i>European Journal of Human Genetics</i> , 2019 , 27, 432-441	5.3	10	
64	Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 109-117	2.4	10	
63	Resistin is associated with breach of tolerance and anti-nuclear antibodies in patients with hepatobiliary inflammation. <i>Scandinavian Journal of Immunology</i> , 2011 , 74, 463-70	3.4	9	
62	C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205. <i>Frontiers in Immunology</i> , 2020 , 11, 622326	8.4	9	
61	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. <i>Clinical and Experimental Immunology</i> , 2018 , 194, 27-38	6.2	9	
60	Uptake of rheumatology biosimilars in the absence of forced switching. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 499-504	5.4	8	
59	Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 1, i23-30	4.3	8	
58	De novo lupus nephritis during treatment with belimumab. <i>Rheumatology</i> , 2021 , 60, 4348-4354	3.9	8	
57	Long-term outcomes of destructive seronegative (rheumatoid) arthritis - description of four clinical cases. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 246	2.8	8	
56	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019 , 46, 492-500	4.1	7	
55	Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2019 , 21, 259	5.7	7	
54	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1387-1393	5.3	6	
53	Anti-CRP autoantibody levels correlate with disease activity in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 35, 65; author reply 66	5.3	6	

(2021-2005)

52	CRP and Anti-CRP Autoantibodies in Systemic Lupus Erythematosus. <i>Current Rheumatology Reviews</i> , 2005 , 1, 81-89	1.6	6
51	High-Frequency Ultrasound of Multiple Arterial Areas Reveals Increased Intima Media Thickness, Vessel Wall Appearance, and Atherosclerotic Plaques in Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2020 , 7, 581336	4.9	6
50	Adverse Pregnancy Outcomes after Multi-Professional Follow-Up of Women with Systemic Lupus Erythematosus: An Observational Study from a Single Centre in Sweden. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
49	Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus. <i>Journal of Immunology Research</i> , 2018 , 2018, 1294680	4.5	6
48	Active NET formation in Libman-Sacks endocarditis without antiphospholipid antibodies: A dramatic onset of systemic lupus erythematosus. <i>Autoimmunity</i> , 2018 , 51, 310-318	3	6
47	SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic. <i>Frontiers in Immunology</i> , 2021 , 12, 724047	8.4	5
46	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	4
45	The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
44	Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021 , 12, 688753	8.4	3
43	Pronounced Diurnal Pattern of Salivary C-Reactive Protein (CRP) With Modest Associations to Circulating CRP Levels. <i>Frontiers in Immunology</i> , 2020 , 11, 607166	8.4	3
42	Longitudinal Analysis of Anti-cardiolipin and Anti-2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients. <i>Frontiers in Medicine</i> , 2021 , 8, 646846	4.9	3
41	Clinically suspected recurrence of gastric carcinoid proved to be hypocomplementaemic urticarial vasculitis syndrome with pulmonary involvement. <i>Scandinavian Journal of Rheumatology</i> , 2015 , 44, 337-	.9 ^{1.9}	2
40	Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus. <i>Lupus</i> , 2020 , 29, 625-630	2.6	2
39	Impaired Microcirculation and Vascular Hemodynamics in Relation to Macrocirculation in Patients With Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2021 , 8, 722758	4.9	2
38	Secretory antibodies to citrullinated peptides in plasma and saliva from rheumatoid arthritis patients and their unaffected first-degree relatives. <i>Clinical and Experimental Immunology</i> , 2020 , 199, 143-149	6.2	2
37	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. <i>Frontiers in Immunology</i> , 2020 , 11, 578848	8.4	2
36	Pentraxin-3 detected in human saliva shows limited correlation with biomarkers associated with systemic inflammation. <i>Apmis</i> , 2021 , 129, 304-313	3.4	2
35	Variants in BANK1 are associated with lupus nephritis of European ancestry. <i>Genes and Immunity</i> , 2021 , 22, 194-202	4.4	2

34	Contributions of de novo variants to systemic lupus erythematosus. <i>European Journal of Human Genetics</i> , 2021 , 29, 184-193	5.3	2
33	Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
32	Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes. <i>Clinical and Experimental Immunology</i> , 2021 , 203, 22-31	6.2	2
31	Disease activity trajectories in rheumatoid arthritis: a tool for prediction of outcome. <i>Scandinavian Journal of Rheumatology</i> , 2021 , 50, 1-10	1.9	2
30	Comment on G ystemic autoimmunity with Castleman-like lymphadenopathy: a diagnostic and therapeutic challengeOreply. <i>Scandinavian Journal of Rheumatology</i> , 2021 , 1-2	1.9	1
29	Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	1
28	P137 De novo lupus nephritis during belimumab treatment 2020 ,		1
27	Synthesis of an Array of Triple-Helical Peptides from Type II Collagen for Multiplex Analysis of Autoantibodies in Rheumatoid Arthritis. <i>ACS Chemical Biology</i> , 2020 , 15, 2605-2615	4.9	1
26	Correspondence on P erformance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities O <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
25	Interaction between the rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1183-1189	2.4	1
24	POS0601 DIFFERENCES IN DRUG SURVIVAL BETWEEN ORIGINATOR AND BIOSIMILAR PRODUCTS AMONG FIRST USERS OF EACH MOLECULE. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 535.2-535	2.4	1
23	POS1169 IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 864-865	2.4	1
22	Elevated free secretory component in early rheumatoid arthritis and prior to arthritis development in patients at increased risk. <i>Rheumatology</i> , 2020 , 59, 979-987	3.9	1
21	Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy. <i>Frontiers in Immunology</i> , 2021 , 12, 722118	8.4	1
20	Usefulness of Clinical and Laboratory Criteria for Diagnosing Autoimmune Liver Disease among Patients with Systemic Lupus Erythematosus: An Observational Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
19	Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study. <i>Frontiers in Immunology</i> , 2021 , 12, 756941	8.4	1
18	Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 1360-1368	2.2	1
17	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. <i>RMD Open</i> , 2021 , 7,	5.9	1

LIST OF PUBLICATIONS

16	Individual variations in treatment decisions by Swedish rheumatologists regarding biological drugs for rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2015 , 44, 265-70	1.9	1
15	The Diagnostic Performance of an Extended Ultrasound Protocol in Patients With Clinically Suspected Giant Cell Arteritis <i>Frontiers in Medicine</i> , 2021 , 8, 807996	4.9	0
14	Successful Treatment of AA Amyloidosis in Ankylosing Spondylitis Using Tocilizumab: Report of Two Cases and Review of the Literature. <i>Frontiers in Medicine</i> , 2021 , 8, 661101	4.9	O
13	Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus. <i>Lupus</i> , 2021 , 30, 1244-1253	2.6	Ο
12	Case Report: Borrelia-DNA Revealed the Cause of Arthritis and Dermatitis During Treatment With Rituximab. <i>Frontiers in Neurology</i> , 2021 , 12, 645298	4.1	O
11	A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunity. <i>Scandinavian Journal of Rheumatology</i> , 2021 , 1-3	1.9	О
10	P1_144 Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden. <i>Rheumatology</i> , 2017 , 56, iii88-iii88	3.9	
9	OP0189 Rate of Cervical Neoplasia in Systemic Lupus Erythematosus: A Nationwide Cohort-Study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 128.2-128	2.4	
8	A3.7 No evidence of cathelicidin being involved in the pathogenesis of lupus and arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A44.2-A45	2.4	
7	THU0042 Autoantibodies against High Mobility Group Box Protein-1 in Systemic Lupus Erythematosus: Association with Disease Activity and Other Antinuclear Antibodies. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 191.1-191	2.4	
6	FRI0172 Utility of Swedish Register Data in Classifying Systemic Lupus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 444.2-444	2.4	
5	Dr. Skogh, et al, reply. <i>Journal of Rheumatology</i> , 2009 , 36, 1834-1834	4.1	
4	AB0321 EFFECT ON RETENTION RATES OF A NOVEL AUTOINJECTOR E-DEVICE IMPLEMENTED IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL; A MULTI-CENTRE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1459.1-1459	2.4	
3	AB0400 PATIENT-REPORTED OUTCOME MEASURES IN SWEDISH PATIENTS WITH RECENT-ONSET SLE VERSUS RA IN THE FIRST 60 MONTHS AFTER DIAGNOSIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1499.2-1500	2.4	
2	THU0345 Presence of Immunoglobulin (IG) A Antibodies against Cardiolipin and 🛭-Glycoprotein-I in The Absence of IGG and IGM in Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 312.1-312	2.4	
1	Response to: Oncreased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself? On Bruzzese and Zullo. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e72	2.4	